- Home
- BRNS vs INMB Comparison
BRNS vs INMB Comparison
Compare BRNS & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRNS
- INMB
- Stock Information
- Founded
- BRNS 2016
- INMB 2015
- Country
- BRNS United Kingdom
- INMB United States
- Employees
- BRNS N/A
- INMB N/A
- Industry
- BRNS Biotechnology: Pharmaceutical Preparations
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- BRNS Health Care
- INMB Health Care
- Exchange
- BRNS Nasdaq
- INMB Nasdaq
- Market Cap
- BRNS 48.3M
- INMB 53.4M
- IPO Year
- BRNS 2021
- INMB 2019
- Fundamental
- Price
- BRNS $1.07
- INMB $1.91
- Analyst Decision
- BRNS Strong Buy
- INMB Buy
- Analyst Count
- BRNS 1
- INMB 4
- Target Price
- BRNS $3.00
- INMB $9.53
- AVG Volume (30 Days)
- BRNS 42.9K
- INMB 822.2K
- Earning Date
- BRNS 11-05-2025
- INMB 10-30-2025
- Dividend Yield
- BRNS N/A
- INMB N/A
- EPS Growth
- BRNS N/A
- INMB N/A
- EPS
- BRNS N/A
- INMB N/A
- Revenue
- BRNS $14,969,000.00
- INMB $50,000.00
- Revenue This Year
- BRNS N/A
- INMB $142.83
- Revenue Next Year
- BRNS N/A
- INMB $14,780.90
- P/E Ratio
- BRNS N/A
- INMB N/A
- Revenue Growth
- BRNS 1766.46
- INMB N/A
- 52 Week Low
- BRNS $0.64
- INMB $1.71
- 52 Week High
- BRNS $2.92
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- BRNS 41.80
- INMB 38.01
- Support Level
- BRNS $1.08
- INMB $1.71
- Resistance Level
- BRNS $1.20
- INMB $2.12
- Average True Range (ATR)
- BRNS 0.10
- INMB 0.12
- MACD
- BRNS -0.01
- INMB 0.04
- Stochastic Oscillator
- BRNS 22.16
- INMB 45.45
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.